From research innovations to start-ups
Since 2012 we have actively commercialized our research and been able to lift many innovations into successful businesses. Currently we’ve been focusing on commercializing research results from fields such as:
- Nanoparticle and nanofiber production
- Ultrasonic cleaning
- Physiological measurements and diagnostics
- Ultrasound therapy and actuation
- Traceable nanometrology
- Food industry & novel ingredients
- Super resolution imaging
- Drug delivery
We emphasize strong IPR on path to successful commercialization. Our portfolio of patents involved in the commercialization of research can be found here.
Healthier fat ingredients for the food industry
Oleoflow’s technology enables the conversion of any edible healthy oil into a solid fat. Our patented technology combines food science and material physics to further allow the tailoring of the structure of the fat.This enables reduced calorie intake and provides an increased satiety effect, without any chemical modifications. In short, all of the good stuff from healthy oils in a solid fat structure!
Oleoflow enables the food industry and consumers the possibility of replacing bad fats with healthy ones, so that you can eat what you love without risking your health or the environment.
Nozzle-free nanofiber production technology. Our patented ultrasound electrospinning technology enables production of variable thickness nanofibers. The fiber diameter can be adjusted on-the-fly allowing spinning of gradient structures.
Nanoform Finland Plc
Global experts in nanotechnology and drug particle engineering that dual listed (Finland + Sweden) on Nasdaq First North Premier in June 2020. Nanoform is an innovative nanoparticle medicine enabling company that supplies best in class nanoforming services. Their platform technology can give failed drug molecules a second chance and double the amount of lead compounds progressing into clinic, leading to a significant in increase in the number of drugs that reach the market. The green particle engineering process produces pure and stable nanoparticles as small as 10 nm using supercritical carbon dioxide.
Developing next generation device for glaucoma screening. There are 250 million people with high intra-ocular pressure (IOP), which can lead to glaucoma and blindness. Screening with current tonometers is uncomfortable to the patient and often requires touching of the eye causing sterility issues. Photono’s first in the world ultrasound non-contact tonometer provides next generation solution for IOP screening devices.
A company creating technology and products for needle-free health & biomarker monitoring. GlucoModicum has discovered and developed a new technology which enables needle-free health monitoring into a consumer product. Holds strong portfolio of products and solutions of which the accuracy and safety of the technology has been validated in clinical pilots.
Article of Glucomodicum’s technology in Tekniikan Maailma.
Former and other ETLA based companies
Founded in 2009 on solid scientific measurement background originating from research work in ETLA. Designs and builds tailor-made measurement devices and instruments for industry and R&D needs. Specialized in demanding, high data rate, real-time data-analysis applications.
Swan Cytologics Inc.
Healthtech company based on ultrasound actuation & therapy research of ETLA. The company, nowadays located in Toronto, Canada, develops SWANglide™ – ultrasound-enhanced needle biopsy to optimize patient outcomes by increasing effectiveness and efficiency of needle biopsies. SWANglide delivers gentle ultrasound energy through the biopsy needle and into the target to increase cell and tissue uptake during sampling and to reduce friction during insertion.
Nanojet Oy was a former spin-out company from ETLA. It developed new optical super-resolution imaging device and tools for calibrated 3D nanoimaging.